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A B S T R A C T
Purpose
Rare missense substitutions and in-frame deletions of BRCA1 and BRCA2 genes present a
challenge for genetic counseling of individuals carrying such unclassified variants. We assessed
the value of tumor immunohistochemical markers in conjunction with genetic and evolutionary
approaches for investigating the clinical significance of unclassified variants.
Patients and Methods
We studied 10 BRCA1 and 12 BRCA2 variants identified in Australian families with breast cancer.
Analyses assumed a prior probability based on revised cross-species sequence alignment methods
assessing amino acid evolutionary conservation and position, combined with likelihoods from data on
co-occurrence with pathogenic mutations in the same gene, segregation analysis, and immunohisto-
chemistry. We specifically explored the value of estrogen receptor, cytokeratin 5/6, and cytokeratin 14
as tumor markers of BRCA1 mutation status.
Results
Posterior probabilities classified 72% of variants. BRCA1 variants IVS181 GT (del exon 18) and
5632 T A (V1838E) were classified as pathogenic, with 99% posterior probability of being
deleterious, and tumor histopathology was particularly important for their classification. BRCA2 variant
classification was improved over previous studies, largely by incorporating the prior probability of
pathogenicity based on amino acid cross-species sequence alignments.
Conclusion
Variant classification was considerably improved by analysis of estrogen receptor, cytokeratin 5/6, and
cytokeratin 14 tumor expression, and use of updated methods estimating the clinical relevance of
amino acid evolutionary conservation and position. These methodologies may assist genetic counsel-
ing of individuals with unclassified sequence variants.
J Clin Oncol 26:1657-1663. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Screening of the breast cancer susceptibility genes
BRCA1 and BRCA2 identifies numerous nucleotide
sequence changes of varying clinical significance.
The effect of rare changes predicted to cause mis-
sense substitutions or in-frame exon deletions is of-
ten not clear, and presents a challenge in the clinical
setting. The scale of the problem is considerable,
with approximately 30% of BRCA1 and 60% of
BRCA2 entries in the Breast Cancer Information
Core database for BRCA1 and BRCA2 variation1
described as unclassified variants (UVs).
An integrated approach to classificationofUVs
inBRCA1 andBRCA2 into high-riskmutations and
neutral variants was developed to define a reliable
protocol for prediction of the clinical significance of
UVs.2 This multifactorial likelihood model used
data on co-occurrence of the UV with pathogenic
mutations in the same gene, segregation in families,
and amino acid physicochemical properties and
evolutionary conservation. The model was used to
estimate the odds of causality, a ratio of the likeli-
hood of the observed data under the hypothesis of
causality to that under the hypothesis of neutrality.
Because themodel cannot distinguish between vari-
ants that are truly benign and those that might be
associated with modest risk, neutral variants are
sometimes alternatively termed to be of low/little
clinical significance (neutral/LCS). We recently re-
vised the model to take into account relevant fea-
tures of BRCA1- and BRCA2-associated tumors,
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including thecharacteristichistopathologyassociatedwithpathogenic
mutations in BRCA1. Use of the revised model classified 56% of 25
unselected UVs (seven of 10 BRCA1 and seven of 15 BRCA2) from
Australian families with breast cancer.3 Fewer BRCA2UVs were clas-
sified, largely because BRCA2 evolutionary predictions were less ro-
bust (fewer cross-species sequenceswere available at that time, relative
to BRCA1), and because BRCA2 mutations are not associated with
very distinctive pathologic features. Overall, these findings suggested
that further extension of the model may improve classification rates,
and that classification ofBRCA2UVs particularly would be improved
withmore robust evolutionary predictions.
Several immunohistochemical (IHC)markers, including tumor
expression of estrogen receptor (ER), cytokeratin 5/6 (CK5/6), cyto-
keratin 14 (CK14), and cytokeratin 17 (CK17) have been shown to be
indicators of BRCA1 mutation status.4-7 We undertook a study to
investigate the clinical significance of a new panel of BRCA1 and
BRCA2UVs identified in Australian families with breast cancer, spe-
cifically exploring the value of a subset of these additional IHCmark-
ers as histopathologic classifiers of BRCA1 tumors, and considering
thepriorprobabilityofpathogenicitybasedon improvedevolutionary
conservation analysis methods.
PATIENTS AND METHODS
Subjects and Laboratory Methodology
Pedigrees with UVs in BRCA1 and BRCA2 were ascertained by the
Kathleen Cuningham Foundation Consortium for Research into Familial
Breast Cancer (kConFab).8 Participants provided written informed consent,
and relevant ethics committees approved the study. A total of 276 individuals
(probands and familymembers) were available for genetic screening. Cancer-
free controls (n 180) from the Australian Breast Cancer Family Study have
been described previously.3 Denaturing high performance liquid chromatog-
raphy and sequencingwere as described previously,3 using primers detailed in
Table1. IHCwasperformedusing standardmethods.6,9The study included23
families with 22 different UVs (Tables 2 and 3).
Protein Modeling
Molecular modeling was carried out on a Silicon Graphics Inc work-
station using the Insight II software package (Accelrys, SanDiego, CA).Mod-
elingwas carriedout on the crystal structure of the ringdomain (1JM7.pdb),10
the BRCA1-COOH terminal (BRCT) repeat region of BRCA1 (1JNX.pdb),11
and the BRCA2 crystal structure published by Shin et al.12
Prior Probability of Pathogenicity From Amino Acid
Conservation and Location of the Mutation in Specific
Known Functional Domains
Missense substitutions and in-frame deletions were classified accord-
ing to their location within one of two recognized functional domains of
the proteins, the C-terminus region containing the BRCA1 BRCT repeats,
defined loosely as amino acids 1396 to 1862, and the BRCA2DNA-binding
domain (DBD; amino acids 2500 to 3098). Variants were further catego-
rized according to whether the wild-type residue involved in the substitu-
tion/deletion was evolutionarily conserved through to the pufferfish
Tetraodon, using multiple sequence alignments. Heterogeneity analysis of
1,433 variants in the Myriad Genetics Laboratory database was used to
estimate the proportion of deleterious variants in three classifications13:
invariant position in BRCT/DBD domain, proportion  0.73; variable
Table 1. DHPLC Primer Sequences and Conditions
Variant
Sequence DHPLC Melt
Temperature
Used (°C)Forward (53) Reverse (53)
BRCA1 655 AG ( Y179C) GGAAACCAGTCTCAGTGTCCA CACTTCCCAAAGCTGCCTAC 58
BRCA1 1575 TC (F486L) TGGGAAAACCTATCGGAAGA CCGTTTGGTTAGTTCCCTGA 57
BRCA1 1767 AC (N550H) CCTACATCAGGCCTTCATCC AGGTTCAGCTTTCGTTTTGAA 56
BRCA1 2596 CA (T826K) GGCACTCAGGAAAGTATCTCG AATGACTGGCGCTTTGAAAC 58
BRCA1 2878 TC (V920A) ACATTCTCTGCCCACTCTGG TTTCGTTGCCTCTGAACTGA 57
BRCA1 3415 CT (P1099L)
BRCA1 3446 AC (K1109N)
CCAGTGATGAAAACATTCAAGC GCATGACTACTTCCCATAGGC 55
BRCA1 3827 TG (N1236K) ATTTGGCTCAGGGTTACCG TGCCTTTGCCAATATTACCTG 58
BRCA1 IVS 18  1 GT (del exon 18) GAGGCTCTTTAGCTTCTTAGGAC CCAGCATCACCAGCTTATCT 56
BRCA1 5632 TA (V1838E) AGGACCCTGGAGTCGATTG GCAGTCAGTAGTGGCTGTGG 61
BRCA2 281 GA (R18H) CGTAGGTAAAAATGCCTATTGGA TGTGGTTAACCTGCAAACGA 56
BRCA2 1766 AG (K513R) TCTTGCAGTAAAGCAGGCAAT AGGAGTCCTCCTTCTGTGAGC 56
BRCA2 2048 AC (K607T) TTTGCTCACAGAAGGAGGACT TGCTTCAAACTGGGCTGAAC 56
BRCA2 3031 GA (D935N) TAACTGTCAATCCAGACTCTG CTATATTCAAGGAGATGTCCG 55
BRCA2 3743 CT (S1172L) GAAGAGTACATTTGAAGTGCCTGA CCCCTAAACCCCACTTCATT 58
BRCA2 4391 CA (T1388N) GAATTTGATGGCAGTGATTCAA TTTTGCTCCGTTTTAGTAGCA 54
BRCA2 5506 TG (S1760A) GACAAAAATCATCTCTCCGAAAA CAGTTTGTGGGTATGCATTTG 55
BRCA2 7643 AC (K2472T) CATTGATGGACATGGCTCTG GGGAAAACCATCAGGACATT 55
BRCA2 7772 CT (T2515I) CAAGTCTTCAGAATGCCAGAGA CACTCTGTCATAAAAGCCATCAG 60
BRCA2 8377 GT (A2717S) TGCAAAAACACTTGTTCTCTGTG CAGTACATCTAAGAAATTGAGCATCC 58
BRCA2 8801 AG (Q2858R) TGCCTGGCCTGATACAATTA TGTCCCTTGTTGCTATTCTTTG 57
BRCA2 9078 GT (K2950N)
BRCA2 9133 GA (V2969M)
TGGTCACAGGGTTATTTCAGTG GCTTACAATACGCAACTTCCA 58
BRCA2 9345 GA (del exon 23) CATACAGTTAGCAGCGACAAAAA CCTCAGAACAAGATGGCTGA 56
Abbreviation: DHPLC, denaturing high performance liquid chromatography.
Also known as P3039P.
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position in BRCT/DBD domain, proportion 0.08; and position outside
of BRCT/DBD domain whether invariant or variable, proportion 0.02.
The values were then used as prior probabilities of being deleterious for
classification of the studied variants.
Co-Occurrence With Pathogenic Mutations
Wequeried theMyriad Genetic Laboratories database of approximately
90,000 full-sequence tests to determine the number of times a UV was ob-
served, and the number of different deleterious mutations observed to co-
occurwith each variant, as ameasure of the number of times theUV is seen in
trans with a deleterious mutation. Phase of the variant and mutation was
established for a subset of individuals.Observations for variantswere excluded
if in cis with amutation, included if in trans with amutation, and assumed to
be in trans with at least n-1 observations for n observations with different
deleterious mutations of unknown phase.14
Histopathology and Pedigree Causality Analysis
Available invasive tumor sections were analyzed by two pathologists
(S.L., L.Da.S.) blind to UV status, for parameters recognized to be associated
with BRCA1 or BRCA2mutation status.6,15,16 IHC scoring was performed by
a single pathologist (S.L.) as described previously.6
Pedigree Causality Analysis, Derivation of
Probabilities, Multifactorial Likelihood Scoring
Bayes factor analysiswas asdescribedpreviously.3,13,17 Probabilitieswere
derived for eachof the following components, under the assumption that each
factor was independent. For the co-occurrence component, we estimated the
likelihood that aUVwas causal as described previously.2 The Bayes factor was
included directly as a likelihood ratio (LR) score for the pedigree analysis
component. For BRCA1, ER, CK5/6, and CK14 expression was used for
calculating histopathologic LR scores, based on the previously reported
Table 2. BRCA1 Unclassified Variants–Likelihood Scores and Posterior Probability of Pathogenicity
BRCA1 Unclassified Variant
Conserved to
Tetraodon and in
BRCT Domain
Sequence
Alignment Prior
Probability
Myriad
ER CK 5/6 CK 14
Overall
GradeFrequency
No. of Different
Deleterious Mutations
Estimated in Trans
655 AG (Y179C) Outside .02 104 3 Positive Negative Negative 2
1575 TC (F486L) Outside .02 106 3 Positive Negative Negative 2
1767 AC (N550H) Outside .02 103 3 Positive Negative Negative 2
2596 CA (T826K) Outside .02 67 3 NA NA NA 0
2878 TC (V920A)† Outside .02 1 0 NA NA NA 0
3415 CT (P1099L) Outside .02 42 2 NA NA NA 0
Positive Negative Negative 1
Positive Negative Negative 1
3446 AC (K1109N)‡ Outside .02 11 0 Negative NA NA 3
3827 TG (N1236K) Outside .02 68 0 NA NA NA 0
5632 TA (V1838E) Variable, inside .08 2 0 Negative NA Positive 3
IVS 18  1 GT Invariant, inside .73 4 0 Negative Positive Positive 3
Negative Positive Negative 3
del exon 18 Negative Positive Positive 3
Negative NA Positive 3
Negative Positive Negative 3
Negative Positive Negative 3
BRCA1 Unclassified Variant
LR
Co-Occurrence LR Pathology
Bayes Odds for
the Variant Odds for Causality
Intermediate
Classification
Posterior Probability
of a Variant Being
Deleterious
Classification
With Sequence
Alignment
655 AG (Y179C) 8.49093E-07 0.143 0.0007 8.49942E-11 Neutral/LCS 1.73458E-12 Neutral/LCS
1575 TC (F486L) 9.1225E-07 0.143 0.0007 9.13162E-11 Neutral/LCS 1.8636E-12 Neutral/LCS
1767 AC (N550H) 0.0000008 0.143 0.0007 8.200E-11 Neutral/LCS 1.673E-12 Neutral/LCS
2596 CA (T826K) 0.0000002 1 0.4985 0.0000001 Neutral/LCS 2.291E-09 Neutral/LCS
2878 TC (V920A)† 1.0365238 1 0.9811 1.0169335 Unclassified 0.0203318 Unclassified
3415 CT (P1099L) 0.0000336 0.020449 0.00222216 1.528E-09 Neutral/LCS 3.119E-11 Neutral/LCS
3446 AC (K1109N)‡ 1.4837894 2.95 0.0078 0.0341420 Unclassified 0.0006963 Neutral/LCS
3827 TG (N1236K) 11.465478 1 0.2975 3.4109796 Unclassified 0.0650814 Unclassified
5632 TA (V1838E) 1.0743817 626.912 5.9 3973.9023 Pathogenic 0.9971145 Pathogenic
IVS 18  1 GT (del exon 18) 1.1542960 7561.5232 12.87 112332.40 Pathogenic 0.9999967 Pathogenic
NOTE. The Posterior Probability is calculated from the prior probability (based on sequence data) and the Odds for Causality using Bayes rule. Example calculation of
posterior probability, for variant BRCA1 V1838E: the Prior Probability for V1838E is .08 since variant is inside the BRCT domain but is not conserved (see Patients and
Methods). The Odds for Causality is 3973.9023, calculated as the product of the individual statistically independent components (LR Co-occurrence [1.0743817]  LR
Pathology [626.912]  LR Segregation [5.9]). Note the Intermediate Classification is based on the Odds for Causality, where a variant with odds greater than 1,000:1 is
considered pathogenic, and a variant with odds less than 1:100 is considered neutral/LCS (after Goldgar et al2). The Posterior Probability for V1838E is 0.9971145 Posterior
Odds/(Posterior Odds1), where the Posterior Odds  Prior Probability (.08)  Odds for causality (3973.9023)  (1/1-prior probability).
Abbreviations: BRCT, BRCA1 C-terminus domain; ER, estrogen receptor status; CK5/6, cytokeratin 5/6 status; CK14, cytokeratin 14 status; LR, likelihood ratio; LCS,
low clinical significance; NA, not available.
These three variants occur in cis in a single family. All tumor information is thus derived from a single tumor. A breast-affected individual from the same family
has subsequently been reported to carry the pathogenic mutation BRCA1 546 GT (E143X).
†A pathogenic mutation BRCA1 5622 CT (R1853X) was subsequently identified in an affected individual in a distant branch of the family.
‡The youngest affected member of the family was also subsequently found to carry BRCA1 546 GT (E143X) in addition to the unclassified variant.
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prevalence of the combined immunotypes of these independent predictors
of BRCA1mutation status in breast tumors.6 The likelihoods for causality
were: ER positive (irrespective of CK score) 0.14:1; negative for all three
markers 0.87:1; ER negative, CK14 negative, CK5/6 positive 5.6:1; ER
negative, CK14 positive, CK5/6 negative 2.6:1; ER negative, CK14 posi-
tive, CK5/6 positive  27.4:1. Categories were collapsed for scoring the
single ER-negative, CK14-positive tumor lacking CK5/6 data (LR, 8.8:1).
The likelihood was calculated from ER expression and grade (LR, 2.95:1),
as previously described,3 for the single ER-negative grade 3 tumor lacking
CKdata. ForBRCA2, tubule formationwas used for LR estimates, based on
the previously reported prevalence of this independent predictor ofBRCA2
mutation status.16 Likelihoods were: tubule formation in less than 10% of
tumor 1.2:1; tubule formation10% 0.5:1, as used previously.3
The individual LRs were multiplied to calculate an overall multifac-
torial likelihood ratio assuming statistical independence of the sources of
information. Bayes rule was then used to calculate a posterior probability
that the variant was deleterious from the multifactorial LR, and the prior
probability determined from sequence alignment. Variants with a poste-
rior probability 0.99 were classified as pathogenic, and those with proba-
bility.001were classified as neutral/LCS. Example calculations are provided
in Tables 2 and 3.
RESULTS
Weanalyzeda total of 10BRCA1UVsand12BRCA2UVs in this study
(Tables 2 and 3). All UVs were predicted missense substitutions,
except for two in-frame exon deletions, BRCA1 IVS181 GT (del
exon 18) andBRCA2 9345GA (del exon 23). All UVs fell in regions
reported to interact with at least one other protein thought to be
involved in DNA repair. Protein modeling predictions were possible
for only two variants: BRCA1 5632 TA (V1838E) in the BRCT
Table 3. BRCA2 Unclassified Variants–Likelihood Scores and Posterior Probability of Pathogenicity
BRCA2 Unclassified
Variant
Conserved to
Tetraodon and
in DBD Domain
Sequence
Alignment Prior
Probability
Myriad
Tubule
Formation (%)
LR
Co-OccurrenceFrequency
No. of Different
Deleterious Mutations
Estimated in Trans
281 GA (R18H) Outside .02 5 0  75 1.1328651
1766 AG (K513R) Outside .02 9 0  10 1.2517591
 10
2048 AC (K607T)† Outside .02 6 0  10 1.1614856
3031 GA (D935N) Outside .02 205 5  75 0.0000133
 10
 10
3743 CT (S1172L) Outside .02 62 1  10 4.6968833
5506 TG (S1760A) Outside .02 1 0  75 1.0252638
7643 AC (K2472T) Outside .02 2 0 10-75 1.0511659
7772 CT (T2515I) Variable, inside .08 141 3  10 0.0018610
8377 GT (A2717S) Variable, inside .08 257 4 NA 0.0012803
8801 AG (Q2858R) Variable, inside .08 11 0 10-75 1.3158066
9078 GT (K2950N)‡ Variable, inside .08 196 2 10-75 0.1927832
9345 GA (del exon 23) Invariant, inside .73 28 0 NA 2.0109347
BRCA2 Unclassified
Variant
LR
Pathology
Bayes Odds for
the Variant
Odds for
Causality
Intermediate
Classification
Posterior Probability
of a Variant Being
Deleterious
Classification With
Sequence
Alignment
281 GA (R18H) 0.5 0.01990 0.0112720 Unclassified .0002300 Neutral/LCS
1766 AG (K513R) 1.44 0.00400 0.0072101 Neutral/LCS .0001471 Neutral/LCS
2048 AC (K607T)† 1.2 0.18660 0.2600799 Unclassified .0052797 Unclassified
3031 GA (D935N) 0.72 2.70000 0.0000259 Neutral/LCS .0000005 Neutral/LCS
3743 CT (S1172L) 1.2 0.00786 0.0443145 Unclassified .0009036 Neutral/LCS
5506 TG (S1760A) 0.5 1.17000 0.5997793 Unclassified .0120924 Unclassified
7643 AC (K2472T) 0.5 0.00001 0.0000053 Neutral/LCS .0000001 Neutral/LCS
7772 CT (T2515I) 1.2 0.93200 0.0020814 Neutral/LCS .0001810 Neutral/LCS
8377 GT (A2717S) 1 0.12110 0.0001550 Neutral/LCS .0000135 Neutral/LCS
8801 AG (Q2858R) 0.5 0.93800 0.6171133 Unclassified .0509291 Unclassified
9078 GT (K2950N)‡ 0.5 0.04385 0.0042263 Neutral/LCS .0003674 Neutral/LCS
9345 GA (del exon 23) 1 1.12000 2.2522468 Unclassified .8589445 Unclassified
NOTE. The Posterior Probability is calculated from the prior probability (based on sequence data) and the Odds for Causality using Bayes rule. Example Calculation
of posterior probability, for variant BRCA2 R18H: the Prior Probability for R18H is .02 since variant is outside the DBD domain (see Patients and Methods). The Odds
for Causality is 0.0112720, calculated as the product of the individual statistically independent components (LR Co-occurrence (1.1328651)  LR Pathology (0.5) 
LR Segregation (0.01990)). Note the Intermediate Classification is based on the Odds for Causality, where a variant with odds greater than 1,000:1 is considered
pathogenic, and a variant with odds less than 1:100 is considered neutral/LCS (after Goldgar et al2). The Posterior Probability for R19H is .0002300  Posterior
Odds/(Posterior Odds  1), where the Posterior Odds  Prior Probability (.02)  Odds for causality (0.0112720)  (1/1  prior probability).
Abbreviations: DBD, BRCA2 DNA-binding domain; LR, likelihood ratio; LCS, low clinical significance; NA, not available.
Members of this family were found to carry the BRCA1 2080delA (Stop700) pathogenic mutation.
†Some members of this family also carry BRCA1 5622 CT (R1835X).
‡Two families were included in the analysis. An additional family carrying BRCA2 9132 del C (STOP 2975) in cis with the unclassified variant was excluded
from study.
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domain, and BRCA2 5506 TG (S1760A) in the BRAF35 interaction
domain. The BRCA1 V1838E substitution creates a charged hydro-
philic group in a hydrophobic patch, and the glutamine side chain is
predicted to clash with the Leu1790 side chain, and to a lesser extent
with thePhe1761 side chain. This alterationmight thus be expected to
have serious effects on protein structure. The BRCA2 S1760A substi-
tution is between the BRCA2 repeat 5 (1664 to 1698) and repeat 6
(1837 to 1871), and would not cause a major effect on protein
structure, butmay be important in that it would remove a potential
N-linked glycosylation site. Screening of controls for all UVs under
study identified a single UV, BRCA1 1767 AC (N550H), in
1/180 controls.
Amino acid position and sequence alignment analysis was used
to group missense substitutions into categories, as described in the
Patients and Methods section. Overall, eight variants fell within the
BRCT/DBDdomains, only twoofwhichwere conserved toTetraodon
(Tables 2 and 3). Prior probabilities were assigned according to cate-
gory, for inclusion in the multifactorial analysis.
All the UVs seen in these families have been identified at least
once by Myriad Genetic Laboratories Inc. Five BRCA1 and five
BRCA2 UVs were considered to co-occur in trans with at least one
known deleterious mutation in the same gene, and phase was proven
to be in trans at least once for all but one (BRCA2 3743 CT
[S1172L]). LRs based on co-occurrence alone were indicative of neu-
trality/LCS for five of five BRCA1UVs and three of five BRCA2UVs
with co-occurrent mutations. Furthermore, a homozygote with
BRCA2 3031 GA (D935N) and no clinical features of Fanconi ane-
mia has been identified in theMyriad data set, further suggesting that
this variant is neutral/LCS. Segregation analysis provided firm evi-
dence regarding causality for eight UVs, including the single family
carrying theBRCA1655AG(Y179C), 1575TC(F486L), and1767
AC (N550H) variants in cis.
There was at least one tumor sample available for pathology
review and IHC screening for all but two BRCA1 and one BRCA2
UVs (Tables 2 and 3). The specific BRCA1 histopathologic features
included in LR estimates provided evidence thatBRCA1 5632TA
V1838E and IVS181 GT (del exon 18) were likely pathogenic.
All these tumors were ER negative and high grade, all five with
available CK5/6 data expressed this basal marker of BRCA1muta-
tion status, and CK14 was expressed in four of seven tumors. No
other tumors from carriers of BRCA1 UVs displayed cytokeratin
expression consistent with a BRCA1 mutation. Of the 14 BRCA2
tumors screened, one of two tumors for K513R had histopatho-
logic features of BRCA1 tumors (high grade, ER negativity, focal
positivity for CK14). This result was consistent with the fact that
this individual (but not the other relative screened) was found
to carry a BRCA1 pathogenic mutation during the course of
this study.
The combined odds of causality for each variant were derived as
described in the Patients and Methods section, including LRs for
pathology, co-occurrence, and segregation data, to generate an inter-
mediate classification. Of the 10BRCA1UVs studied, five were classi-
fied as neutral/LCS and two as pathogenic. The overall classification
rate was less for the 12BRCA2UVs, with six classified as neutral/LCS.
After combination of the multifactorial odds with prior probabilities
basedonsequenceanalysis, twoBRCA1variants (2878TC[V920A];
3827 TG [N1236K]), and four BRCA2 variants (2048 AC
[K607T]; 5506TG[S1760A]; 8801AG[Q2858R]; 9345GA[del
exon 23]) remained unclassified.
DISCUSSION
Our study shows that multifactorial likelihood analysis, in combi-
nation with prior probabilities based on evolutionary and physico-
chemical conservation, is a valuable tool to evaluate clinically
problematic BRCA1/2 sequence variants. This approach classified
72% of the 22 UVs studied. Only two BRCA1 UVs (5632 TA
[V1838E] and IVS181 GT [del exon 18]) were classified as
pathogenic, and there was strong evidence for pathogenicity (86%
posterior probability of being deleterious) for one BRCA2 variant,
9345 GA (del exon 23). This highlights the general understand-
ing that the majority of UVs are individually of little clinical im-
portance, based on the fact that the number of UVs far exceeds the
proportion of families linked to BRCA1 or BRCA2 but with no
identified pathogenic mutation. Both BRCA1 variants fall within
or span the BRCTmotifs, domains well recognized to be critical for
BRCA1 function, while BRCA2 exon 23 spans the BUBR1A/Fil-
aminA/BCCI p-alpha interaction sites and contains residues con-
served to Arabidopsis.
The interpretation from protein modeling data was also consis-
tent with final classification. BRCA1 V1838E was predicted to have a
serious effect on protein structure, and this variant was classified as
pathogenic. Likewise, evidence frommodeling of BRCA2 5506 TG
(S1760A)wasmore equivocal, and this variant remained unclassified.
Results from control screening supported our previous suggestion
that this approach might be a simple adjunct to UV evaluation for
nonfounder populations,3 with a neutral/LCS classification for the
single UV observed in controls. While underpowered to evaluate
pathogenicity of rare variants, it is a useful prescreen to exclude com-
mon variation in little studied population groups.
As shownpreviously, themost informative components of the
multifactorial likelihood predictions were co-occurrence and ped-
igree analyses. Co-occurrence scores alone were sufficient to clas-
sify six UVs (27%), and odds from segregation analysis classified
eight UVs (36%), including three variants in cis. A total of 11 UVs
(50%) could be classified considering only co-occurrence and seg-
regation data.
Information from tumors was available for most UVs, but
only addedweight to the final classification for the subset of patho-
genic BRCA1 UVs. This indicates that ER and cytokeratin IHC
would be very helpful in the classification of likely pathogenic
BRCA1UVs. Although cytokeratin IHC is not yet routinely carried
out in all diagnostic laboratories, the  scores for agreement on
staining positivity of CK5/6 and CK14 reported for a large data set
were 0.74 to 0.82 (SE, 0.06 to 0.07), corresponding to concor-
dance rates of 88% to 92%.6 This suggests that cytokeratin staining
could be introduced into routine histopathologic practice, espe-
cially in larger centers, to provide information for evaluation of
BRCA1 UVs. In our experience, CK5/6 and CK14 IHC can be
implemented relatively easily if appropriate quality controls are in
place—as most pathology laboratories practice routinely. We rec-
ognize that the IHC approach relies on the underlying assump-
tion that missense and in-frame deletions will exhibit the same
tumor histopathologic characteristics as truncating mutations,
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but have confidence that it is valid for classification of high-risk
BRCA1 mutations from our published17a and unpublished data
showing that functionally deficient BRCA1 RING and BRCT do-
main missense substitutions exhibit immunohistopathologic pro-
files consistent with a BRCA1mutation.
Pathology scores for BRCA2 UVs were not very informative
individually, but in two instances contributed to the final classifica-
tion. In this study, we did not include analysis of tumor loss of het-
erozygosity for BRCA1 and BRCA2, as done previously,3 because
analysis of this and our previous data set revealed statistically
significant increased loss of the variant compared with what is
expected for the underlying hypothesis used previously to calculate
likelihood estimates.
Sequence alignment analysis was useful for refining the clas-
sification, especially for BRCA2 variants. The increased value of
this approach over our previous study3 was largely due to increas-
ing the informativeness with additional sequences in the BRCA2
alignment, and the incorporation of estimates of prior probabili-
ties based on both alignment and location within functionally
important domains. BRCA1 and BRCA2 protein multiple se-
quence alignments used for this analysis (or updated versions
thereof) are publically available through the web-based program
and alignments at http://agvgd.iarc.fr (International Agency for
Research on Cancer; Align GVHD). Thus, investigators could use
this resource to estimate prior probabilities for any BRCA1 or
BRCA2 missense substitutions of interest. However, the clinical
application of the methods presented in this study should be un-
dertaken only with consideration of the caveats associated with the
approaches, principally that prior probabilities and likelihood ra-
tio estimates were derived assuming that variants were either neu-
tral or of similar high risk as the average BRCA1/2mutation,18 and
from analysis of single data sets for the prior probability, co-
occurrence and histopathology components, and that likelihoods
are valid for patients with familial breast cancer. Moreover, it is
likely that further development of sequence information-based
estimates of prior probability to incorporate the physicochemical
characteristics of unclassified variants as assessed by Align GVGD
analysis14 will refine different classes of substitutions, and thus
improve the precision of the prior probabilities associated with
individual substitutions.
Few of the UVs studied here have been analyzed previously, and
none using the range of approaches we examined. Comparisons to
larger studies with several points of evidence are not inconsistent
with our findings. Co-occurrence and evolutionary conservation
analysis of BRCA1missense variants14,19 classified BRCA1 Y179C,
F486L, N550H, and P1099L as neutral/LCS, and another study
found F486L to be absent in 1054 ethnicity-matched controls, but
failed to classify it using a multifactorial approach based on odds
derived from tumor information, bilaterality, and family history of
ovarian cancer.20 The BRCA1 T826K and BRCA2 S1172L, T2515I,
and A2717S UVs were all reported to be present in the proband
from at least one German family with breast/breast-ovarian cancer
but absent from 200 ethnically matched controls.21 The BRCA2
K2950N variant was observed in a patient with familial prostate
cancer, but also in two of 340 normal chromosomes, supporting
the neutral/LCS classification from this study.22
Few variants have been studied functionally. The splice site
variant BRCA2 9345 Gthan A has been reported to cause an
in-frame deletion of exon 23 from reverse transcription polymer-
ase chain reaction studies of peripheral blood lymphocyte RNA.23
The T2515I amino acid substitution was shown to be associated
with normal expression levels, complete ablation of cell survival
activity, partial inactivation of homologous recombination and
centrosome regulatory functions, and a cytoplasmic-nuclear local-
ization profile intermediate between the aberrant predominantly
nuclear localization of known mutations and the cytoplasmic lo-
calization for wild-type BRCA2.24 These data suggest this alter-
ation has a subtle effect on BRCA2 function, and is thus unlikely to
be associated with a high risk of cancer. Indeed, the same study
reported low odds in favor of causality from segregation analysis,24
and our multifactorial analysis classified T2515I as neutral/LCS.
In summary, we have provided evidence for the classification
of 16 of 22 different BRCA1 or BRCA2 sequence variants. Our
findings support the general understanding13 that the majority of
unclassified variants of BRCA1 and BRCA2 are not associated with
a high risk of disease as associated with classical truncating muta-
tions. Classification of individual variants is necessary to identify
the subset demonstrating features of classical mutations with high
risk of disease, and is considerably improved by analysis of ER,
CK5/6, and CK14 tumor expression, and updated methods to
estimate the clinical relevance of amino acid evolutionary conser-
vation and position. These methodologies may be easily imple-
mented, and together with supporting information provided by
additional studies such as functional assays, may assist genetic
counseling of unclassified sequence variants.
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